Teleflex (NYSE:TFX) Issues FY 2026 Earnings Guidance

Teleflex (NYSE:TFX) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 6.250-6.550 for the period, compared to the consensus EPS estimate of 6.730. The company issued revenue guidance of $2.3 billion-$2.3 billion, compared to the consensus revenue estimate of $2.3 billion.

Teleflex Price Performance

Shares of TFX traded up $1.49 during midday trading on Friday, hitting $133.17. 935,893 shares of the company traded hands, compared to its average volume of 968,091. The stock has a 50-day moving average of $119.44 and a 200-day moving average of $116.73. Teleflex has a one year low of $100.18 and a one year high of $139.67. The firm has a market cap of $5.89 billion, a P/E ratio of -6.48, a PEG ratio of 0.89 and a beta of 0.82. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.54 and a quick ratio of 2.01.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, May 7th. The medical technology company reported $1.39 earnings per share for the quarter, topping the consensus estimate of $1.21 by $0.18. The company had revenue of $548.30 million for the quarter, compared to analysts’ expectations of $536.91 million. Teleflex had a negative net margin of 30.56% and a positive return on equity of 14.30%. Teleflex’s revenue for the quarter was up 32.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.44 earnings per share. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. As a group, sell-side analysts predict that Teleflex will post 6.77 EPS for the current fiscal year.

Teleflex Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 31st. Investors of record on Friday, March 6th were given a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 1.0%. The ex-dividend date was Friday, March 6th. Teleflex’s dividend payout ratio is -6.62%.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on TFX. Needham & Company LLC upped their price objective on shares of Teleflex from $138.00 to $147.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Wells Fargo & Company upped their price objective on shares of Teleflex from $130.00 to $138.00 and gave the stock an “equal weight” rating in a research report on Friday. Mizuho set a $140.00 price objective on shares of Teleflex in a research report on Friday. Wall Street Zen upgraded shares of Teleflex from a “sell” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Raymond James Financial reiterated an “outperform” rating and set a $150.00 price target on shares of Teleflex in a research report on Friday. Three analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $142.86.

More Teleflex News

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Teleflex beat Q1 estimates, reporting adjusted EPS of $1.39 versus $1.21 expected and revenue of $548.3 million versus $536.9 million expected, which signals solid execution in the quarter. Article Title
• Positive Sentiment: The company maintained its full-year 2026 outlook and announced plans for a buyback, which can support investor confidence and share price performance. Article Title
• Positive Sentiment: Wells Fargo raised its price target on TFX from $130 to $138, implying modest upside from current levels and suggesting improved analyst sentiment. Article Title
• Neutral Sentiment: Management’s earnings call commentary was described as balanced, with growth offset by margin strain, indicating the business is still navigating profitability pressure even after the earnings beat. Article Title
• Negative Sentiment: Teleflex’s updated FY2026 EPS guidance of $6.25 to $6.55 came in below the market’s expectation of about $6.73, which could limit enthusiasm despite the quarterly beat. Article Title

Institutional Trading of Teleflex

A number of institutional investors have recently made changes to their positions in TFX. AQR Capital Management LLC lifted its stake in Teleflex by 478.1% in the third quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company’s stock worth $287,603,000 after acquiring an additional 1,956,811 shares during the period. Arrowstreet Capital Limited Partnership lifted its stake in Teleflex by 123.9% in the third quarter. Arrowstreet Capital Limited Partnership now owns 660,800 shares of the medical technology company’s stock worth $80,855,000 after acquiring an additional 365,663 shares during the period. Gumshoe Capital Management LLC purchased a new stake in Teleflex in the fourth quarter worth $31,432,000. Integral Health Asset Management LLC purchased a new stake in Teleflex in the fourth quarter worth $30,510,000. Finally, Walleye Capital LLC lifted its stake in Teleflex by 270.8% in the fourth quarter. Walleye Capital LLC now owns 319,168 shares of the medical technology company’s stock worth $38,951,000 after acquiring an additional 233,102 shares during the period. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.